Indoleamine 2,3-dioxygenase (IDO) in inflammation and allergy to Aspergillus

被引:21
|
作者
Romani, Luigina [1 ]
Zelante, Teresa
De Luca, Antonella
Bozza, Silvia
Bonifazi, Pierluigi
Moretti, Silvia
D'Angelo, Carmen
Giovannini, Gloria
Bistoni, Francesco
Fallarino, Francesca
Puccetti, Paolo
机构
[1] Univ Perugia, Microbiol Sect, Dept Expt Med & Biochem Sci, I-06122 Perugia, Italy
关键词
inflammation; Aspergillus; Indoleamine; 2; 3-dioxygenase; Th17; cells; Regulatory T cells; TOLL-LIKE RECEPTORS; REGULATORY T-CELLS; NF-KAPPA-B; TRYPTOPHAN CATABOLISM; INNATE; TOLERANCE; FUMIGATUS; ACTIVATION; INHIBITION; IMMUNITY;
D O I
10.1080/13693780802139867
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Innate responses combine with adaptive immunity to generate the most effective form of resistance against Aspergillus fumigatus. A complex set of signaling networks initiate both innate and adaptive immunity in response to the different fungal morphotypes. In response, the fungus has developed or acquired sophisticated mechanisms to avoid, counteract and subvert sensors, signaling networks and a range of effector functions that constitute the host immune response. Host response and fungal countermeasures may contribute to the balance of pro-inflammatory and anti-inflammatory signaling that is eventually required to benefit both parties. Here we highlight the important contribution of the enzyme IDO (indoleamine 2,3-dioxygenase) and tryptophan catabolites to such a homeostatic condition in Aspergillus infection and allergy. By providing the host with immune defense mechanisms adequate for protection, without necessarily eliminating the fungus or causing an unacceptable level of tissue damage, IDO and tryptophan metabolites may prove to be potent regulators capable of taming innate and adaptive pathogenic inflammatory host responses.
引用
收藏
页码:S154 / S161
页数:8
相关论文
共 50 条
  • [1] The indoleamine 2,3-dioxygenase (IDO) pathway controls allergy
    von Bubnoff, D.
    Bieber, T.
    ALLERGY, 2012, 67 (06) : 718 - 725
  • [2] Synthesis of indoleamine 2,3-dioxygenase (IDO) inhibitor
    Suzuki, Takafumi
    Yokoyama, Yuuaku
    Tsutumi, Katsuhiko
    Yamaguchi, Tomoyuki
    Takikawa, Osamu
    Okuno, Hiroaki
    JOURNAL OF MOLECULAR CATALYSIS B-ENZYMATIC, 2010, 62 (01) : 114 - 115
  • [3] Indoleamine 2,3-dioxygenase (IDO):: the antagonist of type IIFN driven skin inflammation?
    Scheler, M.
    Bieber, T.
    Tueting, T.
    Wenzel, J.
    von Bubnoff, D.
    EXPERIMENTAL DERMATOLOGY, 2007, 16 (03) : 216 - 217
  • [4] THERAPEUTIC EFFECT OF INDOLEAMINE 2,3-DIOXYGENASE (IDO) INHIBITOR IN THE MALE GENITAL INFLAMMATION
    Ohira, Shin
    Hara, Ryoei
    Tone, Shigenobu
    Nagai, Atsushi
    SEXUALLY TRANSMITTED INFECTIONS, 2019, 95 : A75 - A75
  • [5] Indoleamine 2,3-dioxygenase (IDO) inhibitors and cancer immunotherapy
    Fujiwara, Yu
    Kato, Shumei
    Nesline, Mary K.
    Conroy, Jeffrey M.
    DePietro, Paul
    Pabla, Sarabjot
    Kurzrock, Razelle
    CANCER TREATMENT REVIEWS, 2022, 110
  • [6] Indoleamine 2,3-dioxygenase (Ido) inhibitors and their nanomedicines for cancer immunotherapy
    Guo, Yixuan
    Liu, Yu
    Wu, Wei
    Ling, Daishun
    Zhang, Qiao
    Zhao, Peng
    Hu, Xi
    BIOMATERIALS, 2021, 276
  • [7] Indoleamine 2,3-Dioxygenase in Intestinal Immunity and Inflammation
    Cherayil, Bobby J.
    INFLAMMATORY BOWEL DISEASES, 2009, 15 (09) : 1391 - 1396
  • [8] Indoleamine 2,3-Dioxygenase (Ido) As A New Immunological Marker In Kidney
    Loiacono, Elisa
    Votta, Barbara
    Amore, Alessandro
    Peruzzi, Licia
    Puccinelli, Maria Paola
    Camilla, Roberta
    Vergano, Luca
    Guido, Giuliana
    Donadi, Maria Elena
    Coppo, Rosanna
    PEDIATRIC NEPHROLOGY, 2013, 28 (08) : 1525 - 1526
  • [9] Indoleamine 2,3-dioxygenase (IDO): Biology and Target in Cancer Immunotherapies
    Selvan, Senthamil R.
    Dowling, John P.
    Kelly, William K.
    Lin, Jianqing
    CURRENT CANCER DRUG TARGETS, 2016, 16 (09) : 755 - 764
  • [10] Indoleamine 2,3-Dioxygenase (IDO) silencing for improved antitumour vaccination
    Macagno, M.
    Bolli, E.
    Marchini, C.
    Amici, A.
    Riganti, C.
    Bosia, A.
    Forni, G.
    Cavallo, F.
    EJC SUPPLEMENTS, 2010, 8 (05): : 75 - 75